Concepedia

Abdul Rafeh Naqash

AR

45

Publications

3.1K

Citations

29

H-Index

2017

Active since

Affiliations

East Carolina University(Current)

Imperial College London

The University of Texas MD Anderson Cancer Center

National Cancer Institute

The University of Kansas Cancer Center

Abdul Rafeh Naqash is an author at East Carolina University specializing in medicine, oncology, and pathology.

ORCID

Top concepts

Publications per year

2017–2025

45

Publications

45

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

Bairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash et al. · JAMA Oncology · 2020 · 472 citations · Full text

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

Chipman Stroud, Aparna Hegde, Cynthia R. Cherry et al. · Journal of Oncology Pharmacy Practice · 2017 · 316 citations

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida et al. · Hepatology · 2022 · 218 citations · Full text

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Hamzah Abu‐Sbeih, Faisal S. Ali, Abdul Rafeh Naqash et al. · Journal of Clinical Oncology · 2019 · 192 citations · Full text

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

Hamzah Abu‐Sbeih, David M. Faleck, Biagio Ricciuti et al. · Journal of Clinical Oncology · 2019 · 188 citations · Full text

Rows per page

1–5 of 45